Stage | Tumor and node | 5-year survival (%) | Work-up pre-SOT | Time interval to transplantation | Additional considerations |
I | T1aN0 | 92 | PET-CT; consider biopsy post-SBRT | ≥3 years | |
T1bN0 | 83 | PET-CT; consider biopsy post-SBRT | ≥3 years | ||
T1cN0 | 77 | PET-CT; consider biopsy post-SBRT | 3 to 5 years | 5-year recurrence-free survival is safest | |
IB | T2aN0 | 68 | PET-CT | 5 years | |
IIA | T2bN0 | 60 | PET-CT | 5 years | |
IIB | T3 N0 | 53 | PET-CT | 5 years | |
IIIA | 36 | PET-CT | 5 years | Special caution with N2 disease | |
IIIB | 26 | N/A | N/A | Not an SOT candidate | |
IIIC | 13 | N/A | N/A | Not an SOT candidate | |
IVA | 10 | N/A | N/A | Not an SOT candidate | |
IVB | 0 | N/A | N/A | Not an SOT candidate |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟